Form 4: Rhythm Pharmaceuticals Director Jennifer L. Good Receives Equity Compensation

Rhythm Pharmaceuticals, Inc. Director Jennifer L. Good was granted 7,037 stock options and 4,712 restricted stock units as part of her compensation.

Summary

• Jennifer L. Good, a Director of Rhythm Pharmaceuticals, Inc. (RYTM), reported the acquisition of equity securities.
• The filing details the grant of 7,037 stock options with an exercise price of $63.66 per share.
• Additionally, 4,712 Restricted Stock Units (RSUs) were granted, each representing a contingent right to receive one share of common stock.
• Both the stock options and RSUs were granted on June 24, 2025.
• The stock options have an expiration date of June 23, 2035.
• Both grants are subject to vesting, which occurs upon the earlier of June 24, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders in 2026, contingent on Ms. Good's continued service.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it represents a standard, expected compensation event that aligns director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of equity compensation aligns the interests of Director Jennifer L. Good with those of the shareholders, incentivizing long-term performance.
• This is a standard practice for compensating board members, reflecting ongoing commitment to corporate governance and strategic oversight.

Future Outlook

The equity grants are forward-looking, with vesting contingent on the director's continued service through June 24, 2026, or the day prior to the 2026 annual meeting, aligning future incentives with company performance.

Industry Context

The granting of stock options and restricted stock units to directors is a common and widely accepted practice across the biotechnology and pharmaceutical industries. It serves to attract and retain experienced board members and align their financial interests with the long-term success of the company and its shareholders.

Comparison to Industry Standards

• The compensation structure, involving a mix of stock options and restricted stock units, is consistent with typical equity compensation packages for non-employee directors in publicly traded biotechnology companies.
• The vesting schedule, tied to continued service and future annual meetings, is a standard mechanism to ensure ongoing commitment and oversight from board members.

Corporate Governance

Related Party Transactions

• The grant of equity compensation to a director is a related party transaction, as directors are considered related parties to the company. This transaction is part of the standard compensation framework for board members.

Stakeholder Impact

• Shareholders: The equity grants align the director's incentives with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: While not directly impacting employees, the compensation structure for directors reflects the company's overall approach to incentivizing key personnel.

Next Steps

• The stock options and restricted stock units will vest upon the earlier of June 24, 2026, or the day immediately prior to the Issuer's next annual meeting of the stockholders to be held in 2026, subject to Jennifer L. Good's continued service.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Corporate Governance, Biotechnology, Pharmaceuticals